GlassScriptPhysician profile
Zhicheng Li
NPI 1740365063
$26,575.67
in general payments reported to CMS, 2019-2025
48 companies · $4,009 in 2025
The $4,009 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.27 · 2020: $431 · 2021: $942 · 2022: $2,294 · 2023: $11K · 2024: $8,099 · 2025: $4,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $8,778 · Travel and Lodging: $15.41 · Education: $2.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,043.75 |
| Food and Beverage | $8,777.86 |
| Travel and Lodging | $15.41 |
| Education | $2.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16,222.65 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,496.80 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbott Laboratories | $949.32 | 2022-2025 | Eterna, Proclaim |
| Lundbeck LLC | $945.81 | 2020-2025 | Vyepti |
| Lilly USA, LLC | $587.17 | 2022-2025 | Kisunla, Emgality, Amyvid |
| Nevro Corp. | $500.94 | 2021-2024 | Senza |
| Alexion Pharmaceuticals, INC. | $479.05 | 2023-2025 | Ultomiris, Soliris |
| Eisai INC. | $446.39 | 2023-2025 | |
| Pfizer INC. | $404.51 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $346.95 | 2022 | |
| Impel Pharmaceuticals INC. | $284.24 | 2023 | Trudhesa |
| Axsome Therapeutics, INC. | $267.20 | 2025 | Symbravo |
| Ucb, INC. | $258.61 | 2024-2025 | Zilbrysq, Rystiggo |
| Impel Pharmaceuticals LLC | $257.40 | 2024-2025 | Trudhesa |
| Amgen INC. | $257.07 | 2020-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhicheng Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.